Podcast Episodes
Back to Search328: Pfizer's activist troubles, gene therapy questions, RFK Jr.'s MAHA ambitions
Will an activist investor campaign against Pfizer lead to big changes at the struggling Pharma giant? Why are some experts questioning the regulatory…
1 year, 11 months ago
327: Biotech's next gold rush, GLP-1 shortages, and STAT Summit highlights
Elaine, Allison, and Adam chat about investors' interest in using CAR-T to treat autoimmune conditions, the latest developments with the supply of El…
2 years ago
326: Crypto for CRISPR, a new RNAi startup, & a Nobel for AI
First, biotech veteran John Maraganore calls in to discuss his new startup, City Therapeutics, this week's Nobel Prize awards, and the nerdy accolade…
2 years ago
325: Biden's health care AI czar, a new obesity company, and its dealmaking CEO
Our colleague Mohana Ravindranath joins us to talk about Micky Tripathi, charged with coordinating how AI is used across different government agencie…
2 years ago
From Tradeoffs: Race to the Bottom
We’re excited to share the first episode in a new podcast series on generic drugs from Tradeoffs. It’s called ‘Race to the Bottom,’ and each week the…
2 years ago
324: Genentech's cancer pivot, Pfizer's sickle cell withdrawal, and a new schizophrenia drug
Our colleague Jonathan Wosen joins us to discuss the recent setbacks and wins in oncology R&D, including Genentech's decision to shut down its cancer…
2 years ago
323: Cannabinoids for weight loss, a cancelled ad comm, and the Fed lowers interest rates
Mizuho analyst Jared Holz joins us to discuss what the Federal Reserve's long-awaited decision to lower interest rates means for biotech stocks and s…
2 years, 1 month ago
322: A new threat to Merck's blockbuster cancer treatment, Moderna's cutbacks, and obesity drugs for kids
STAT reporter Matt Herper joins us to break down all the angles of this week's tumultuous week in cancer immunotherapy, including his up-close look a…
2 years, 1 month ago
321: Summit's upcoming cancer results, Recursion's mixed data, and the next big obesity target
We discuss the next big trend in obesity drug development — treatments that target the amylin hormone. Companies argue that these types of drugs coul…
2 years, 1 month ago
320: Jim Wilson's next venture, a surprise startup shutdown, & Lilly's Zepbound strategy
STAT biotech reporter Jonathan Wosen joins us to discuss gene therapy pioneer Jim Wilson's exit from his decades-long tenure at the University of Pen…
2 years, 1 month ago